ReviewLipids in health and disease2025
Epicardial adipose tissue: an overtly concealed contributor to cardiovascular events in chronic kidney disease patients.
Review in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Epicardial adipose tissue, a metabolically active visceral fat depot surrounding the heart, is increasingly implicated as a key contributor to cardiovascular disease in patients with chronic kidney disease. This review explores how chronic kidney disease induced metabolic dysregulation, chronic inflammation and uremic toxin accumulation lead to epicardial adipose tissue dysfunction. Pathologically altered epicardial adipose tissue promotes atherosclerosis, myocardial fibrosis and arrhythmogenesis through paracrine signaling, oxidative stress and direct cellular interactions. Advanced imaging modalities now enable precise epicardial adipose tissue quantification, revealing its correlation with cardiovascular outcomes in chronic kidney disease. Epicardial adipose tissue is expected to become a new target for predicting and assessing cardiovascular risk, and for interventions to reduce cardiovascular risk in chronic kidney disease patients, thereby providing a new direciovascular risk, and for interventions to reduce cardiovascular risk in chronic kidney disease patients, thereby providing a new direction for future risk management and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.